|
|
 Previous Article | Table of Contents | Next Article 
Establishment and characterization of a human plasma cell myeloma culture
having a rearranged cellular myc proto-oncogene
AF Gazdar, HK Oie, IR Kirsch and GF Hollis
Using a serum-free defined medium, we have established a human cell line,
NCI-H929, from a malignant effusion occurring in a patient with IgAk
myeloma. The cultured cells have the morphologic, ultrastructural,
biochemical, immunologic, and cytochemical features of plasma cells. The
cells have rearranged alpha and kappa genes and synthesize and secrete high
amounts of IgAk (greater than 80 micrograms/10(6) cells per 24 hours). The
cells express surface immunoglobulin (alpha and kappa), the plasma cell
antigen PCA-1, the transferrin receptor (T9) and T10 but lack antigens
associated with earlier stages of B cell development (HLA-DR, B1, B2, B4,
CALLA), as well as other leukocyte- macrophage antigens and Epstein-Barr
virus (EBV) nuclear antigen. Although molecular studies confirm that both
the tumor and cultured cells are derived from the same clone of malignant B
cells, the tumor cells were predominantly near-diploid, whereas the
cultured cells are predominantly near-tetraploid with six copies of
chromosome 8, four to six of which have an 8q + abnormality. However, both
the tumor and the cultured cells have a rearrangement of the cellular c-myc
proto- oncogene (located at 8q24) and express c-myc RNA. Although a modest
number of human "plasmacytoid" cell lines have been established, most are
lymphoblastoid lines lacking plasma cell features, while others appear to
be early secretory cells. In contrast, NCI-H929 is a differentiated, highly
secretory human plasma cell line.
Volume 67,
Issue 6,
pp. 1542-1549,
06/01/1986
Copyright © 1986 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. J. J. de Gorter, R. M. Reijmers, E. A. Beuling, H. P. H. Naber, A. Kuil, M. J. Kersten, S. T. Pals, and M. Spaargaren
The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells
Blood,
April 1, 2008;
111(7):
3364 - 3372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Velangi, E. C. Matheson, G. J. Morgan, G. H. Jackson, P. R. Taylor, A. G. Hall, and J. A.E. Irving
DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma
Carcinogenesis,
October 1, 2004;
25(10):
1795 - 1803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. B. Derksen, E. Tjin, H. P. Meijer, M. D. Klok, H. D. Mac Gillavry, M. H. J. van Oers, H. M. Lokhorst, A. C. Bloem, H. Clevers, R. Nusse, et al.
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells
PNAS,
April 20, 2004;
101(16):
6122 - 6127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Bergsagel, M. Chesi, E. Nardini, L. A. Brents, S. L. Kirby, and W. M. Kuehl
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma
PNAS,
November 26, 1996;
93(24):
13931 - 13936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
